Download PDF
Thromb Haemost 1997; 78(01): 133-136
DOI: 10.1055/s-0038-1657515
Venous thromboembolism and cancer, a two-way clinical association
Schattauer GmbH Stuttgart

Prevention of Thrombotic Disorders in Cancer Patients Undergoing Chemotherapy

Mark N Levine
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Rickies FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31
    PubMedGoogle Scholar
  • 2 Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metast Rev 1992; 11: 237-248
    CrossrefPubMedGoogle Scholar
  • 3 Rogers JS, Murgo AJ, Fontana VA, Raich PC. Chemotherapy for breast cnacer decreases plasma protein C and protein S. J Clin Oncol 1988; 06: 276-281
    CrossrefPubMedGoogle Scholar
  • 4 Edwards RL, Klaus M, Mathews E. et al Heparin abolishes the chemotherapy induced increase in plasma fibriopeptide A levels. Am J Med 1990; 89: 25-28
    CrossrefPubMedGoogle Scholar
  • 5 Bertomeu MC, Gallo S, Lauri D. et al Chemotherapy enhances endothelial reactivity to platelets. Clin Exp Metast 1990; 08: 511-518
    CrossrefPubMedGoogle Scholar
  • 6 Levine MN, Gent M, Hirsh J. et al The thrombogenic effect of anticancer drug therapy in women with Stage II breast cancer. N Eng J Med 1988; 318: 404-407
    CrossrefPubMedGoogle Scholar
  • 7 Weiss RB, Tormey DC, Holland JF. et al Venous thrombosis during multimodal treatment of primary breast cancer. Cancer Treat Rep 1981; 65: 677-679
    PubMedGoogle Scholar
  • 8 Goodnough LT, Saito H, Manni A. et al Increased incidence of thromboembolism in stage IV breast caner patients treated with a five-day chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-1268
    CrossrefPubMedGoogle Scholar
  • 9 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol 1991; 09: 286-294
    CrossrefPubMedGoogle Scholar
  • 10 Pritchard KI, Paterson AHG, Paul NA. et al Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-2737
    CrossrefPubMedGoogle Scholar
  • 11 Wall JG, Weiss RB, Norton L. et al Arterial thrombosis associated with adjuvant chemotherapy for breast cancer: a Cancer and Leukemia Group B study. Am J Med 1989; 87: 501-504
    CrossrefPubMedGoogle Scholar
  • 12 Tempelhoff GF, Dietrich M, Hommel G, Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14: 2560-2568
    CrossrefPubMedGoogle Scholar
  • 13 Clahsen PC, van de VeldeCJH, Julien JP. et al Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Breast Cancer Cooperative Group Study. J Clin Oncol 1994; 12: 1266-1271
    CrossrefPubMedGoogle Scholar
  • 14 Fisher B, Redmond C, Legault Poisson. et al Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B16. J Clin Oncol 1990; 08: 1005-1018
    CrossrefPubMedGoogle Scholar
  • 15 Rifkin SE, Green S, Metch B. et al Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal node positive and estrogen receptor positive breast cancer patients: a Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2078-2085
    CrossrefPubMedGoogle Scholar
  • 16 Fisher B, Constantino J, Redmond C. et al A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumours. N Eng J Med 1989; 320: 479-484
    CrossrefPubMedGoogle Scholar
  • 17 Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematolopoietic growth factors — a meta-analysis. Thrombos Haemost 1996; 75: 368-371
    PubMedGoogle Scholar
  • 18 Levine M, Hirsh J, Gent M. et al Double blind randomised trial of very-low-dose warfarin for the prevention of thromboembolism in Stage IV breast cancer. Lancet 1994; 343: 886-889
    CrossrefPubMedGoogle Scholar
  • 19 Rajan R, Gafni A, Levine M, Hirsh J, and Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol 1995; 13: 42-46
    CrossrefPubMedGoogle Scholar
  • 20 Bern MM, Lokich JJ, Wallach SR. et al Very low doses of warfarin can prevent thrombosis in central vein catheters: a randomized prospective trial. Ann Intern Med 1990; 112: 4232-4428
    PubMedGoogle Scholar
  • 21 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep vein thrombosis in cancer patients with venous access devices — prophylaxis with a low molecular weight heparin (fragmin). Thrombos Haemost 1996; 75: 251-253
    PubMedGoogle Scholar
  • 22 Levine MN, Hirsh J, Gent M. et al Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611
    Article in Thieme ConnectPubMedGoogle Scholar